Gapping up
In reaction to strong earnings/guidance:
- TLYS +14.7%, EXPR +13.4%, NGL +10.3%, (also signs definitive agreement to sell remaining propane business for $900 mln), FRO +9%, TECD +7.1%, BURL +5.2%, KEYS +3.2%, KLIC +1.3%, PVH +0.5%
Select metals/mining stocks trading higher:
- X +5.7%, AKS +5.2%, CENX +3.5%, NUE +2.8%, AA +2.5%, RS +1.6%, STLD +1.2%, MT +1.1%, .
Other news:
- CRIS +27.2% (granted Fast Track designation for the development of fimepinostat in patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma by the FDA), SESN +8.9% (prices offering of 22,222,223 shares of its common stock at $1.80 per share), TZOO +5% (still checking), ALV +3.7% (provides guidance metrics ahead of investor day), TTOO +3.7% (prices 6.1 mln common stock offering at $7.50/share), LIVN +3.6% (confirms the U.S. Centers for Medicare & Medicaid Services' is reconsidering its national coverage determination for VNS Therapy for treatment-resistant depression ), SGMO +3.4% (announced today that management will present a corporate overview at the 2018 Jefferies Global Healthcare Conference), GLPG +3% (Gilead Sciences and Galapagos report Phase 2 equator study of filgotinib in psoriatic arthritis achieves primary endpoint; will progress into Phase 3), BCO +2.6% (agreed to purchase Dunbar Armored, the fourth largest U.S. cash management company, for approximately $520 million in cash), SNDX +2.1% (Syndax Pharmaceuticals and Nektar Therapeutics to collaborate in immuno-oncology clinical trial that will evaluate combination of entinostat with NKTR-214 in patients with PD-1 refractory melanoma), GBT +1.5% (ticking higher after FDA places CRISPR and Vertex's sickle cell disease gene therapy on clinical hold), APTO +1.4% (enters $20 mln common share purchase agreement w/ Aspire Capital), CARS +1.2% (after seeing late pop higher on NYPost article suggesting the company hired JPMorgan to consider selling itself), BLUE +1.2% (boosted by CRSP / VRTX news; also assumed with Overweight ratings at Piper Jaffray), FPRX +1% (Five Prime Therapeutics enters into a collaboration with Roche to develop immunohistochemistry (IHC) companion diagnostic assays for use with Five Prime's first-in-class investigational drug candidates), .
Analyst comments:
- GLW +2.1% (upgraded to Overweight from Equal-Weight at Morgan Stanley)
- MOMO +1.6% (upgraded to Buy from Neutral at UBS)
- BIIB +1% (upgraded to Buy from Hold at Canaccord Genuity)
![]()